5-Amino-1MQ: The NNMT Inhibitor That Went from Mouse Study to Biohacker Favorite Before Anyone Tested It in a Human

5-Amino-1MQ is a small molecule NNMT inhibitor — a synthetic compound that blocks the enzyme nicotinamide N-methyltransferase — with consistent preclinical evidence for fat mass reduction in mouse models through a mechanism entirely different from GLP-1 receptor agonism. It is not a peptide. It is grouped in the Weight Loss & Metabolic cluster because it circulates in the same research community alongside peptide-based weight loss compounds and has attracted substantial interest for its proposed fat-specific mechanism.

The compound emerged from academic research at the University of Texas Medical Branch, where Harshini Neelakantan and Stanley Watowich’s group characterized its NNMT inhibition properties between 2017 and 2024. In seven years of published research, the evidence base has grown to include nine primary studies — all in mice, rats, or cell lines. No human pharmacokinetic study, no Phase I safety trial, no clinical dose-finding study has ever been published. The compound went from academic mouse study to commercial research chemical market without passing through any stage of human drug development.

This article examines what the preclinical evidence actually shows, where the mechanism is genuinely interesting, and why the gap between that mechanism and community use represents a qualitatively different risk profile from other compounds in this cluster — most of which have at least some human data.

Quick Facts: 5-Amino-1MQ at a Glance

What Is 5-Amino-1MQ?

Every other weight loss compound in this cluster — semaglutide, tirzepatide, liraglutide, retatrutide — works by telling your brain you are not hungry. They suppress appetite through GLP-1 receptor signaling, and they work spectacularly well because humans eat less when their satiety signals are amplified. 5-Amino-1MQ proposes something different: what if you could make fat cells burn more energy without changing appetite at all? Not by signaling the brain, but by changing the internal chemistry of the fat cell itself. That is the idea behind NNMT inhibition — and it has worked in every mouse study that has tested it.

NNMT — nicotinamide N-methyltransferase — is an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). This is part of the one-carbon metabolism network. NNMT is highly expressed in adipose tissue and liver. When NNMT activity is high in fat cells, more SAM is consumed for nicotinamide methylation, leaving less available for other critical methylation reactions. The downstream result: reduced NAD+ biosynthesis via the salvage pathway, reduced SIRT1 activity, and a metabolic environment that favors fat storage over fat oxidation.

When 5-amino-1MQ inhibits NNMT, it reverses this pattern. SAM consumption for nicotinamide methylation drops. More nicotinamide is diverted toward NAD+ biosynthesis through the salvage pathway (NAMPT → NMN → NAD+). The increased NAD+ activates SIRT1, which deacetylates PGC-1α (mitochondrial biogenesis) and FOXO1 (gluconeogenesis regulation). AMPK is activated via the shifted NAD+/NADH ratio, promoting glucose uptake and fatty acid oxidation.

One critical clarification: 5-amino-1MQ is not a peptide. It is a quaternary amine small molecule with a molecular weight of approximately 159 Da — well below the typical peptide threshold. Its inclusion in the Weight Loss & Metabolic cluster reflects community co-use patterns, not pharmacological classification. Vendors sell it through the same channels as BPC-157, semaglutide, and ipamorelin. Pharmacologically, it belongs in a different category entirely.

Origins and Development

The 5-amino-1MQ story begins at the University of Texas Medical Branch (UTMB) in Galveston, where Harshini Neelakantan and Stanley Watowich’s group systematically characterized quinolinium-based NNMT inhibitors across seven years of published research.

2017: Neelakantan et al. published the foundational structure-activity relationship study in the Journal of Medicinal Chemistry (PMID: 28548833). The team screened a series of quinolinium derivatives and identified 5-amino-1MQ as a potent, membrane-permeable NNMT inhibitor with an IC50 of approximately 1 μM. This was medicinal chemistry groundwork — no animal efficacy data yet.

2018: The same group published the primary in vivo characterization in Biochemical Pharmacology (PMID: 29155147). Diet-induced obese (DIO) mice received approximately 34 mg/kg/day subcutaneously over 11 days. Results: body weight decreased 5.1%, white adipose tissue (WAT) shrank 35%, adipocyte size dropped 30%, and total cholesterol decreased 30%. Crucially, food intake did not change. This was the paper that put 5-amino-1MQ on the research community’s radar.

2019: Neelakantan et al. pivoted to muscle biology in Biochemical Pharmacology (PMID: 30753815). Aged mice (24 months) with BaCl2-induced muscle injury received 5-amino-1MQ. Muscle stem cell activation increased, myofiber cross-sectional area doubled, and peak torque improved approximately 70%. The NAD+ salvage pathway and SIRT1 were implicated.

2021: Awosemo et al. published rat pharmacokinetic data in Journal of Pharmaceutical and Biomedical Analysis (PMID: 34304009). Oral bioavailability was 38.4%. This was the first formal PK characterization, validating an LC-MS/MS assay across IV, oral, and subcutaneous routes.

2022: Dimet-Wiley et al. explored NNMT inhibition combined with caloric restriction in Scientific Reports (PMID: 35013352). The combination produced faster adiposity normalization in DIO mice and established a distinct gut microbiome signature enriched in Lactobacillus.

2024: Two significant papers appeared. Babula et al. published the most comprehensive metabolic study to date in Diabetes, Obesity and Metabolism (PMID: 39161060) — 28-day dose-finding in DIO mice showing dose-dependent weight loss, improved glucose tolerance and insulin sensitivity, attenuated hepatic steatosis with reduced ALT/AST, and full tissue distribution data confirming the compound reaches adipose, muscle, and liver. Separately, Dimet-Wiley et al. published in Scientific Reports (PMID: 38969654) showing 40% grip strength improvement in aged sedentary mice and 60% improvement when combined with exercise.

The compound went from academic publication to commercial availability on the research chemical market within approximately two years of the first in vivo study — without any human testing at any stage.

Mechanism of Action

The NNMT Pathway

NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). This is a node in the one-carbon metabolism network. When NNMT is inhibited by 5-amino-1MQ, SAM consumption for this reaction is reduced. The metabolic shift produces four downstream effects:

1. More intracellular NAD+. Nicotinamide is diverted toward NAD+ biosynthesis via the salvage pathway (NAMPT → NMN → NAD+). NAD+ is a critical cofactor for over 500 enzymatic reactions.

2. SIRT1 activation. NAD+-dependent deacetylase SIRT1 is activated. SIRT1 deacetylates PGC-1α (mitochondrial biogenesis), FOXO1 (gluconeogenesis regulation), and p53 (cellular stress response).

3. AMPK activation. The NAD+/NADH ratio shift activates AMP-activated protein kinase (AMPK), promoting glucose uptake, fatty acid oxidation, and mitochondrial function.

4. Reduced lipogenesis. Decreased MNA production reduces lipogenic gene expression in adipocytes, shifting the balance from fat storage to fat oxidation.

How This Differs from GLP-1 Agonism

The mechanistic difference between 5-amino-1MQ and GLP-1 receptor agonists is fundamental, not incremental. GLP-1R agonists (semaglutide, tirzepatide, retatrutide) work through G protein-coupled receptor signaling: they bind receptors in the brain, pancreas, and gut to suppress appetite, enhance insulin secretion, and delay gastric emptying. The primary weight loss driver is eating less. These are central (brain) and peripheral effects mediated through hormone receptor signaling.

5-Amino-1MQ works through intracellular enzyme inhibition: it enters fat cells and blocks NNMT, redistributing metabolic cofactors (SAM, NAD+) to favor fat oxidation. There is no appetite suppression in any published mouse study. Food intake remained unchanged in Neelakantan 2018. The proposed mechanism is adipose-selective metabolic reprogramming — though the compound distributes systemically, not just to fat.

MOTS-c, another Tier 4 compound in this cluster, converges on AMPK activation through a different upstream pathway — it is an endogenous mitochondrial-derived peptide, not a synthetic small molecule.

Tissue Distribution

Babula et al. 2024 (PMID: 39161060) demonstrated effective tissue distribution to adipose, muscle, and liver after subcutaneous dosing in mice. NNMT is expressed across multiple tissues — the compound distributes systemically, not just to adipose.

Safety implication: SAM is a universal methyl donor for DNA methylation, histone modification, neurotransmitter synthesis (serotonin, dopamine, norepinephrine via COMT), and phospholipid metabolism. Chronic perturbation of SAM metabolism has systemic consequences that are entirely uncharacterized for 5-amino-1MQ in any species.

Key Research Areas and Studies

Obesity and Fat Loss (Primary Research Area)

Study	PMID	Model	Duration	Dose / Route	Key Findings
Neelakantan et al. 2018, Biochem Pharmacol	29155147	DIO mice (C57Bl/6)	11 days	~34 mg/kg/day SC (3×/day)	Body weight ↓5.1%, eWAT ↓35%, adipocyte size ↓30%, cholesterol ↓30%. No food intake change.
Dimet-Wiley et al. 2022, Sci Rep	35013352	DIO mice	Variable	Not specified, oral	CR + NNMT inhibition = faster adiposity normalization. Distinct microbiome with ↑Lactobacillus.
Babula et al. 2024, Diabetes Obes Metab	39161060	DIO mice	28 days	10, 25, 30 mg/kg oral + SC	Dose-dependent ↓weight/fat. ↑Glucose tolerance, ↑insulin sensitivity. ↓Hepatic steatosis, ↓ALT/AST. Full tissue PK.

Muscle Function and Sarcopenia (Emerging Research Area)

Study	PMID	Model	Duration	Key Findings
Neelakantan et al. 2019, Biochem Pharmacol	30753815	Aged mice (24 mo), BaCl2 injury	1–3 weeks	Muscle stem cell activation, myofiber CSA ↑2-fold, peak torque ↑70%. NAD+ salvage pathway + SIRT1 enhanced.
Dimet-Wiley et al. 2024, Sci Rep	38969654	Aged mice (22–24 mo)	8 weeks	Grip strength ↑40% (sedentary), ↑60% (combined w/ exercise). Improved intramyocellular lipid content, ↑gastrocnemius fiber CSA.

Oncology (Exploratory)

Yang et al. 2024 (PMID: 39067875) reported that 5-amino-1MQ reduced tumor growth and enhanced anti-PD-L1 immunotherapy in urothelial bladder cancer mouse models by targeting NNMT in cancer-associated fibroblasts. This is a single study in a single cancer type — preliminary, but it suggests NNMT inhibition may have applications beyond metabolic disease.

Pharmacokinetics

Awosemo et al. 2021 (PMID: 34304009) conducted the only formal PK study. In rats: oral bioavailability 38.4%, mean Cmax 2,252 ng/mL oral, LC-MS/MS assay validated across IV, oral, and SC routes.

Babula et al. 2024 (PMID: 39161060) provided mouse tissue distribution data after SC dosing — effective levels in adipose, muscle, and liver, supporting the claim that the compound reaches metabolically relevant tissues.

Critical note: All PK data is from rodents. No human pharmacokinetic study exists. Rodent-to-human PK translation is notoriously unreliable for metabolic compounds.

Claims vs. Evidence

Claim	What the Evidence Shows	Verdict
“5-amino-1MQ burns fat”	Mouse studies show significant fat mass reduction (↓35% WAT in 11 days, dose-dependent effects over 28 days) via NNMT inhibition → NAD+ → SIRT1/AMPK pathway. Mechanism demonstrated in vitro and in vivo. Zero human data.	Preclinical Only
“Works without changing diet or exercise”	Correct in mouse models — Neelakantan 2018 showed fat loss with no change in food intake. Whether this translates to humans is unknown. Metabolic compensation mechanisms differ between species.	Preclinical Only
“Preserves muscle while burning fat”	Two aged-mouse studies show improved muscle stem cell activation and grip strength (PMID: 30753815, 38969654). May have dual fat-loss + muscle-preservation effects — in mice.	Preclinical Only
“Improves insulin sensitivity”	Babula 2024 (PMID: 39161060) showed improved oral glucose tolerance and insulin sensitivity in DIO mice. Consistent with NAD+/SIRT1/AMPK mechanism. No human glucose or insulin data.	Preclinical Only
“Fixes fatty liver”	Babula 2024 showed attenuated hepatic steatosis, reduced macrophage infiltration, normalized ALT/AST in DIO mice. Promising preclinical signal. No human liver data.	Preclinical Only
“5-amino-1MQ is safe”	No human safety data exists. Mouse studies showed no adverse effects at research doses. Comprehensive toxicology has not been published. Mechanism — altering SAM/NAD+ balance systemically — has unknown long-term consequences.	Insufficient Data
“Boosts NAD+ levels”	Confirmed in vitro: NNMT inhibition increases intracellular NAD+ in adipocytes (Neelakantan 2018). Whether this translates to measurable systemic NAD+ increases in humans is unknown.	Supported (In Vitro)
“Comparable to semaglutide for weight loss”	No comparison is meaningful. Semaglutide has Phase III RCT data in tens of thousands of patients; 5-amino-1MQ has mouse studies from a single lab group. Different universes of evidence.	Not Comparable
“5-amino-1MQ is a peptide”	No. It is a quaternary amine small molecule with MW ~159 Da. Not a peptide by any definition. Marketed alongside peptides due to vendor overlap, not pharmacological classification.	Incorrect
“Community doses of 50–150 mg daily are evidence-based”	No human dose has ever been established. Community doses are extrapolated from mouse studies using allometric scaling — an approach that has failed for numerous compounds in drug development.	No Evidence Base
“Has anti-aging properties”	NNMT inhibition activates NAD+/SIRT1, which overlaps with proposed longevity pathways. Two aged-mouse studies show functional improvements. “Anti-aging” is a marketing claim that no preclinical study can support.	Preclinical Mechanism Only
“Helps with cancer”	One 2024 mouse study (PMID: 39067875) showed NNMT inhibition enhanced immunotherapy in bladder cancer models. Preliminary. Not evidence for anticancer use.	Preliminary (Single Study)

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

This section is the most important in this article, and it can be stated in a single sentence: there is zero published human evidence for 5-amino-1MQ of any kind.

This is not “limited human data.” It is not “early-stage human evidence.” It is a complete absence. No Phase I pharmacokinetic study. No safety trial. No dose-finding study. No efficacy trial. No case reports. No case series. No compassionate use reports. No ClinicalTrials.gov registrations. Nothing.

For context: most compounds in the Weight Loss & Metabolic cluster have at least some human data. Semaglutide, tirzepatide, and liraglutide have Phase III randomized controlled trials in tens of thousands of patients. Retatrutide has Phase II and Phase III data with published dose-finding. Even AOD-9604 — a compound with a weak evidence base — has limited human trial data. 5-Amino-1MQ has none.

The NNMT target itself is legitimate. Multiple pharmaceutical companies have preclinical NNMT programs. Ruf et al. 2022 (PMID: 36104373) published tricyclic NNMT inhibitors being developed through formal drug pipelines. The target is being pursued professionally through standard IND pathways. 5-Amino-1MQ simply reached the unregulated commercial market first — before any human testing at any stage.

Safety, Risks, and Limitations

Known Risks (What We Can Infer)

SAM metabolism disruption. SAM is a universal methyl donor for DNA methylation, histone modification, neurotransmitter synthesis (serotonin, dopamine, norepinephrine via COMT), and phospholipid metabolism. Chronic NNMT inhibition alters SAM/SAH balance systemically. The consequences of this perturbation are entirely uncharacterized in any species at the exposure durations used in the community.

Epigenetic concerns. SAM is the methyl donor for DNA methyltransferases. Altering SAM availability could theoretically affect gene expression patterns — a class of risk that operates on a different timescale than standard pharmacological toxicity. No studies have examined this.

Liver effects. NNMT is highly expressed in the liver. While Babula 2024 showed improved liver histology in DIO mice over 28 days, the long-term consequences of chronic hepatic NNMT inhibition are unknown.

No toxicology data. Comprehensive toxicology studies have not been published. LD50, genotoxicity, reproductive toxicity, carcinogenicity — none characterized.

The “No Human Safety Data” Problem

Source Quality Risk

5-Amino-1MQ is sold as a “research chemical.” There is no pharmaceutical-grade GMP manufacturing. No standardized certificate of analysis requirements. Purity, identity, and contaminant profiles vary by vendor. If you source this compound, demand a third-party certificate of analysis and verify it against a known standard. For more on evaluating source quality, see our Certificate of Analysis Guide.

Regulatory Status

FDA: No IND filed. No classification as a pharmaceutical drug. Research chemical status. Category 3 per the Peptidings regulatory framework — unregulated compound with no active regulatory pathway.

WADA: Not on the 2025 or 2026 Prohibited List. Not classified. This should not be interpreted as safety endorsement — it simply means the substance has not been evaluated by anti-doping authorities.

DEA: Not scheduled.

International: Grey zone in most jurisdictions — the same regulatory space as other unclassified research chemicals. Not specifically prohibited but not approved for human use in any country.

Compounding pharmacies: Some US clinics and compounding pharmacies sell 5-amino-1MQ. This does not constitute FDA approval or endorsement. Compounding pharmacy availability is a market signal, not a regulatory one.

Dosing in Published Research

Study	PMID	Species	Dose	Route	Duration	Notes
Neelakantan 2018	29155147	Mouse (DIO)	~34 mg/kg/day (20 mg/kg × 3)	SC	11 days	Primary characterization
Neelakantan 2019	30753815	Mouse (aged)	5–10 mg/kg	SC	1–3 weeks post-injury	Muscle regeneration
Babula 2024	39161060	Mouse (DIO)	10, 25, 30 mg/kg	Oral + SC	28 days	Dose-finding; dose-dependent effects
Awosemo 2021	34304009	Rat	5, 25, 30 mg/kg	IV, oral, SC	PK study	Oral bioavailability 38.4%

Dosing in Self-Experimentation Communities

Protocol Parameter	Typical Community Range	Evidence Basis
Route	Oral (capsules, liquid)	Oral route used in some mouse studies; rat oral bioavailability 38.4% (PMID: 34304009). No human oral absorption data.
Dose	50–150 mg daily (oral)	Allometric extrapolation from mouse studies. No validated human dose.
Duration	4–12 weeks, cycled	No published data supports any cycling protocol. Community-derived.
Timing	Typically morning, fasted	No published data on timing effects.
Stacking	Often combined with injectable peptides (BPC-157, ipamorelin)	No published data on combinations. Pharmacological interaction profile unknown.

Frequently Asked Questions

Related Compounds

5-Amino-1MQ occupies a unique position in the Weight Loss & Metabolic cluster — it is the only non-peptide, non-GLP-1-class compound, and the only one with zero human data. The comparison below highlights the evidence gap.

Semaglutide vs. 5-amino-1MQ: Different mechanism (GLP-1R agonism vs. NNMT inhibition), different evidence universe (Phase III RCTs in tens of thousands vs. mouse studies from one lab group), different routes (SC injection vs. oral). Not comparable in any clinically meaningful way.

MOTS-c vs. 5-amino-1MQ: Both converge on AMPK activation via different upstream pathways. MOTS-c is an endogenous mitochondrial-derived peptide; 5-amino-1MQ is a synthetic small molecule. Both are Tier 4, preclinical only.

AOD-9604 vs. 5-amino-1MQ: AOD-9604 has limited human trial data (Tier 3 on Peptidings, though evidence quality is debated); 5-amino-1MQ has none. Different mechanisms — AOD-9604 is a GH C-terminal fragment.

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Weight Loss Efficacy	Route	Mechanism Class	Key Differentiator
Semaglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~7 days	FDA-approved (Wegovy, Ozempic)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III)	Subcutaneous injection (weekly)	GLP-1 agonist	Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding
Tirzepatide	Synthetic dual GLP-1R/GIPR agonist peptide	GLP-1R / GIPR	~5 days	FDA-approved (Zepbound, Mounjaro)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III SURMOUNT-3)	Subcutaneous injection (weekly)	Dual GLP-1/GIP agonist	Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism
Retatrutide	Synthetic triple GLP-1R/GIPR/GcgR agonist peptide	GLP-1R / GIPR / GcgR	~5 days	Phase III clinical trials (not yet approved)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 24% body weight reduction (Phase II)	Subcutaneous injection (weekly)	Triple GLP-1/GIP/glucagon agonist	Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression
Liraglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~13 hours	FDA-approved (Saxenda, Victoza)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 8% body weight reduction (Phase III SCALE)	Subcutaneous injection (daily)	GLP-1 agonist	First GLP-1 RA approved for weight management. Daily dosing. Well-established long-term safety data
Orforglipron	Non-peptide small-molecule GLP-1 receptor agonist	GLP-1R	~11 hours	FDA-approved (Foundayo)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 15% body weight reduction (Phase II interim)	Oral (small molecule)	GLP-1 agonist (oral)	First oral non-peptide GLP-1 RA approved for weight management. Room-temperature stable, no injection required
CagriSema	Synthetic fixed-ratio combination (semaglutide + cagrilintide)	GLP-1R / AmylinR	~7 days (semaglutide) / ~7 days (cagrilintide)	Phase III clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 20% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/amylin dual agonist	Combines GLP-1 RA with long-acting amylin analog. Amylin pathway targets satiety and gastric emptying synergistically
Survodutide	Synthetic dual GLP-1R/GcgR agonist peptide	GLP-1R / GcgR	~3–4 days	Phase II clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase II)	Up to 18% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/glucagon dual agonist	Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists
AOD-9604	Modified fragment of GH (amino acids 177–191)	GH mimetic (fragment-based)	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — as GH fragment	Tier 3 — Pilot / Limited Human Data	~2–3% body weight reduction (limited human data)	Subcutaneous injection	GH C-terminus analog (lipolytic)	Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims
5-Amino-1MQ	Synthetic small molecule quinone metabolite analog	NNMT inhibitor	~6–8 hours	Not FDA-approved	Not WADA-listed — emerging research compound	Tier 4 — Preclinical Only	~5–8% body weight reduction (mouse models only; limited human data)	Oral (small molecule)	NNMT inhibition (NAD+ pathway)	Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published
MOTS-c	Synthetic mitochondrial open-reading-frame peptide (13 amino acids)	AMPK activator (AMP-kinase pathway)	~2–4 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 4 — Preclinical Only	Modest weight reduction (animal models); no published human trials	Subcutaneous injection	Mitochondrial-derived peptide analog	Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published
Tesamorelin	Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification)	GHRH-R	~26 minutes	FDA-approved (Egrifta for lipodystrophy in HIV)	Prohibited — S2 (GHRH analog)	Tier 1 — Approved Drug	~2–4% visceral fat reduction (HIV lipodystrophy indication)	Subcutaneous injection (daily)	GHRH analog	Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations

Summary and Key Takeaways

5-Amino-1MQ is a mechanistically interesting NNMT inhibitor with consistent animal data and zero human evidence — the widest evidence-to-use gap of any compound in the Weight Loss & Metabolic cluster.

Key Takeaways

1. Not a peptide. 5-Amino-1MQ is a quaternary amine small molecule with a molecular weight of approximately 159 Da. Its inclusion in peptide vendor catalogs reflects marketing, not pharmacology.
2. NNMT is a legitimate pharmacological target. Multiple pharmaceutical companies are pursuing NNMT inhibitors through formal drug development pipelines. The target itself has scientific credibility.
3. Preclinical data is internally consistent. Fat mass reduction, improved insulin sensitivity, hepatic steatosis improvement, and muscle stem cell activation have been demonstrated across nine studies — all in mice, rats, or cell lines.
4. Zero human data of any kind. No pharmacokinetics. No safety data. No dose-finding. No efficacy trial. No case reports. The compound skipped every stage of human drug development.
5. Community use is operating entirely ahead of the evidence base. People are taking a compound that has never been tested in a human being at any dose for any duration.
6. Not WADA prohibited. No FDA classification. Research chemical status. The absence of regulatory attention reflects the compound’s obscurity, not its safety.
7. The mechanism — altering SAM/NAD+ balance — has systemic implications. SAM is the universal methyl donor for DNA methylation, neurotransmitter synthesis, and epigenetic regulation. Chronic perturbation is uncharacterized.

Verdict Recapitulation

5-Amino-1MQ earns the “Thin Ice” verdict because its entire evidence base consists of mouse studies from a single lab group, no human safety or efficacy data exists at any dose, and its mechanism — systemic perturbation of SAM/NAD+ metabolism — carries uncharacterized risks that operate on timescales no animal study has examined. The preclinical signal is mechanistically interesting and internally consistent. But interesting preclinical data is not evidence for human use. If you use this compound, you are the clinical trial, and there is no safety net.

Where to Source 5-Amino-1MQ

Further Reading and Resources

If you want to go deeper on 5-amino-1MQ, the evidence landscape for weight loss compounds, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• MOTS-c — AMPK pathway overlap, different upstream mechanism (mitochondrial-derived peptide).
• AOD-9604 — Another non-GLP-1 weight loss compound with limited human data.
• Semaglutide — FDA-approved GLP-1R agonist, strongest evidence base in the cluster.
• Tirzepatide — Dual GLP-1R/GIPR agonist, Phase III weight loss data.
• Weight Loss & Metabolic Cluster Hub — All compounds in this cluster with comparative evidence tiers.
• Evidence Levels Explained — Understanding the Peptidings tier system.
• How to Read a Research Study — Separating signal from noise in published papers.
• Certificate of Analysis Guide — What to verify when sourcing research compounds.
• Half-Lives and Dosing Intervals — Pharmacokinetic basics for informed decisions.

External Resources

• PubMed — Biomedical Research Database — Search for “5-amino-1MQ” or “NNMT inhibitor” to access published studies.
• ClinicalTrials.gov — Check for registered or ongoing trials (currently none).

Selected References and Key Studies

1. Neelakantan H, et al. “Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.” J Med Chem. 2017;60(12):5015–5028. PubMed
2. Neelakantan H, et al. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochem Pharmacol. 2018;147:141–152. PubMed
3. Neelakantan H, et al. “Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle.” Biochem Pharmacol. 2019;163:481–492. PubMed
4. Awosemo O, et al. “Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies.” J Pharm Biomed Anal. 2021;205:114255. PubMed
5. Akar S, et al. “Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.” J Obstet Gynaecol. 2021;41(5):819–822. PubMed
6. Dimet-Wiley A, et al. “Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.” Sci Rep. 2022;12:484. PubMed
7. Babula JJ, et al. “Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction.” Diabetes Obes Metab. 2024;26(11):5272–5282. PubMed
8. Dimet-Wiley AL, et al. “Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice.” Sci Rep. 2024;14:15554. PubMed
9. Yang M, et al. “NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.” J Immunother Cancer. 2024;12(7):e009281. PubMed
10. Ruf S, et al. “Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.” Sci Rep. 2022;12:15440. PubMed
11. Sun WD, et al. “Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome.” Front Pharmacol. 2024;15:1410479. PubMed
12. Park J, et al. “Exploring NNMT: from metabolic pathways to therapeutic targets.” Arch Pharm Res. 2024;47(11-12):970–985. PubMed
13. Zhang CY, et al. “Nicotinamide N-methyltransferase in non-alcoholic fatty liver disease.” Arch Biochem Biophys. 2025;765:110283. PubMed
14. Jawaria, et al. “Nicotinamide N-methyltransferase in Cardiovascular Diseases.” Biomolecules. 2025;15(9):1281. PubMed